Skip to product information
1 of 1

FITC Human Anti-Human integrin α4β7 (LPAM-1) Antibody (S-4614)

FITC Human Anti-Human integrin α4β7 (LPAM-1) Antibody (S-4614)

Catalog Number: S0B81245 Application: FCM Reactivity: Hu Conjugation: FITC Brand: Starter
Price:
Regular price $130 USD
Regular price Sale price $130 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Human
Antigen integrin α4β7 (LPAM-1)
Location Membrane
Accession P13612、P26010
Clone Number S-4614
Antibody Type Recombinant mAb
Isotype IgG1
Application FCM
Reactivity Hu
Positive Sample Human peripheral blood cells
Purification Protein A
Concentration 0.2 mg/ml
Conjugation FITC
Physical Appearance Liquid
Storage Buffer

PBS, 1% BSA, 0.09% sodium azide

Stability & Storage

12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

Dilution


application dilution species
FCM 5μl per million cells in 100μl volume Hu

Background

Integrin α4β7 is a heterodimeric transmembrane glycoprotein composed of α4 (CD49d) and β7 (CD29) subunits linked by non-covalent bonds, belonging to the integrin family that primarily mediates cell-cell and cell-matrix adhesion. Its extracellular domain specifically recognizes and binds to ligands, including mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expressed on vascular endothelial cells and the CS-1 fragment of fibronectin. The most critical physiological function of this integrin is to serve as a key "homing molecule" for lymphocyte trafficking to gut-associated lymphoid tissue (GALT) and the intestinal lamina propria—when α4β7 on the surface of naive or memory T cells binds to MAdCAM-1 expressed on high endothelial venules (HEVs) of the intestine, it initiates a cascade of adhesion events, mediating lymphocyte rolling, firm adhesion, and transendothelial migration, thereby guiding these cells to preferentially home to the intestinal mucosal immune system, where it plays an irreplaceable role in maintaining intestinal immune homeostasis and local defense. However, dysregulation of α4β7 function is also closely associated with the pathogenesis of various diseases: in inflammatory bowel diseases (such as Crohn's disease and ulcerative colitis), aberrantly high expression of this integrin on gut-homing lymphocytes drives excessive inflammatory cell infiltration, exacerbating chronic mucosal damage in the intestine. Therefore, it has become an important therapeutic target for these conditions. Anti-α4β7 monoclonal antibodies (such as Vedolizumab), by specifically blocking its binding to MAdCAM-1, can effectively inhibit lymphocyte homing to the gut, thereby achieving selective suppression of local intestinal inflammation in clinical practice without affecting systemic immune function. Additionally, in HIV-1 infection, α4β7 has also been identified as an adhesion receptor for the viral envelope protein gp120, participating in viral dissemination within the intestinal mucosa and the establishment of latent reservoirs.

Picture

FC

Flow cytometric analysis of α4β7 (LPAM-1) expression on human peripheral blood cells. Human peripheral blood cells were stained with either FITC Human IgG1 Isotype Control (left panel) or SDT FITC Human Anti-Human integrin α4β7 (LPAM-1) Antibody (right panel) at 5 ul/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.